GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes

S. Tuuli Karhu; Sini M. Kinnunen; Marja Tölli; Mika J. Välimäki; Zoltan Szabo; Virpi Talman; Heikki Ruskoaho

doi:10.1007/s00204-020-02711-8

GATA₄-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes

S. Tuuli Karhu, Sini M. Kinnunen, Marja Tölli, Mika J. Välimäki, Zoltan Szabo, Virpi Talman, Heikki Ruskoaho

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Archives of Toxicology
Volume	94
Issue number	6
Pages (from-to)	2113-2130
Number of pages	18
ISSN	0340-5761
DOIs	https://doi.org/10.1007/s00204-020-02711-8
Publication status	Published - Jun 2020
MoE publication type	A1 Journal article-refereed

Fields of Science

Doxorubicin
Cardiotoxicity
Human induced pluripotent stem cell-derived cardiomyocytes
Transcription factors
GATA4-targeted compounds
Cardioprotective
TRANSCRIPTION FACTORS GATA4
BRAIN NATRIURETIC PEPTIDE
INDUCED CARDIOMYOPATHY
GENE-EXPRESSION
CELL-SURVIVAL
CARDIAC HORMONES
POSITION PAPER
RAT
PHARMACOKINETICS
HYPERTROPHY
1182 Biochemistry, cell and molecular biology
317 Pharmacy

Access to Document

10.1007/s00204-020-02711-8Licence: CC BY

Karhu2020_Article_GATA4-targetedCompoundExhibitsFinal published version, 6.94 MBLicence: CC BY

Cite this

Karhu, S. T., Kinnunen, S. M., Tölli, M., Välimäki, M. J., Szabo, Z., Talman, V., & Ruskoaho, H. (2020). GATA₄-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. Archives of Toxicology, 94(6), 2113-2130. https://doi.org/10.1007/s00204-020-02711-8

@article{42e10b8ba357460ca12abb37414a5802,

title = "GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes",

keywords = "Doxorubicin, Cardiotoxicity, Human induced pluripotent stem cell-derived cardiomyocytes, Transcription factors, GATA4-targeted compounds, Cardioprotective, TRANSCRIPTION FACTORS GATA4, BRAIN NATRIURETIC PEPTIDE, INDUCED CARDIOMYOPATHY, GENE-EXPRESSION, CELL-SURVIVAL, CARDIAC HORMONES, POSITION PAPER, RAT, PHARMACOKINETICS, HYPERTROPHY, 1182 Biochemistry, cell and molecular biology, 317 Pharmacy",

author = "Karhu, {S. Tuuli} and Kinnunen, {Sini M.} and Marja T{\"o}lli and V{\"a}lim{\"a}ki, {Mika J.} and Zoltan Szabo and Virpi Talman and Heikki Ruskoaho",

year = "2020",

month = jun,

doi = "10.1007/s00204-020-02711-8",

language = "English",

volume = "94",

pages = "2113--2130",

journal = "Archives of Toxicology",

issn = "0340-5761",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

Karhu, ST , Kinnunen, SM, Tölli, M, Välimäki, MJ, Szabo, Z, Talman, V & Ruskoaho, H 2020, 'GATA₄-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes', Archives of Toxicology, vol. 94, no. 6, pp. 2113-2130. https://doi.org/10.1007/s00204-020-02711-8

GATA₄-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. / Karhu, S. Tuuli ; Kinnunen, Sini M.; Tölli, Marja et al.
In: Archives of Toxicology, Vol. 94, No. 6, 06.2020, p. 2113-2130.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo

T2 - establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes

AU - Karhu, S. Tuuli

AU - Kinnunen, Sini M.

AU - Tölli, Marja

AU - Välimäki, Mika J.

AU - Szabo, Zoltan

AU - Talman, Virpi

AU - Ruskoaho, Heikki

PY - 2020/6

Y1 - 2020/6

KW - Doxorubicin

KW - Cardiotoxicity

KW - Human induced pluripotent stem cell-derived cardiomyocytes

KW - Transcription factors

KW - GATA4-targeted compounds

KW - Cardioprotective

KW - TRANSCRIPTION FACTORS GATA4

KW - BRAIN NATRIURETIC PEPTIDE

KW - INDUCED CARDIOMYOPATHY

KW - GENE-EXPRESSION

KW - CELL-SURVIVAL

KW - CARDIAC HORMONES

KW - POSITION PAPER

KW - RAT

KW - PHARMACOKINETICS

KW - HYPERTROPHY

KW - 1182 Biochemistry, cell and molecular biology

KW - 317 Pharmacy

U2 - 10.1007/s00204-020-02711-8

DO - 10.1007/s00204-020-02711-8

M3 - Article

SN - 0340-5761

VL - 94

SP - 2113

EP - 2130

JO - Archives of Toxicology

JF - Archives of Toxicology

IS - 6

ER -

Karhu ST , Kinnunen SM, Tölli M, Välimäki MJ, Szabo Z, Talman V et al. GATA₄-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. Archives of Toxicology. 2020 Jun;94(6):2113-2130. Epub 2020 Mar 17. doi: 10.1007/s00204-020-02711-8